245 related articles for article (PubMed ID: 16207074)
1. Darbepoetin alfa: its use in anemia associated with chronic kidney disease.
Robinson DM; Easthope SE
BioDrugs; 2005; 19(5):327-43. PubMed ID: 16207074
[TBL] [Abstract][Full Text] [Related]
2. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
3. Darbepoetin alfa: a novel erythropoiesis-stimulating protein.
Cases A
Drugs Today (Barc); 2003 Jul; 39(7):477-95. PubMed ID: 12973399
[TBL] [Abstract][Full Text] [Related]
4. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
5. Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease.
Hudson JQ; Sameri RM
Pharmacotherapy; 2002 Sep; 22(9 Pt 2):141S-149S. PubMed ID: 12222584
[TBL] [Abstract][Full Text] [Related]
6. Darbepoetin alfa.
Ibbotson T; Goa KL
Drugs; 2001; 61(14):2097-104; discussion 2105-6. PubMed ID: 11735636
[TBL] [Abstract][Full Text] [Related]
7. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
Agarwal A; Silver MR; Walczyk M; Liu W; Audhya P
J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537
[TBL] [Abstract][Full Text] [Related]
8. Darbepoetin alfa: a new therapy for the management of anaemia associated with chronic kidney disease.
Lindberg J
Expert Opin Biol Ther; 2002 Dec; 2(8):977-84. PubMed ID: 12517275
[TBL] [Abstract][Full Text] [Related]
9. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease.
Suranyi MG; Lindberg JS; Navarro J; Elias C; Brenner RM; Walker R
Am J Nephrol; 2003; 23(2):106-11. PubMed ID: 12481149
[TBL] [Abstract][Full Text] [Related]
10. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies.
Scott SD
Pharmacotherapy; 2002 Sep; 22(9 Pt 2):160S-165S. PubMed ID: 12222586
[TBL] [Abstract][Full Text] [Related]
11. Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease.
Silver MR; Agarwal A; Krause M; Lei L; Stehman-Breen C
Am J Geriatr Pharmacother; 2008 Jun; 6(2):49-60. PubMed ID: 18675764
[TBL] [Abstract][Full Text] [Related]
12. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
Wilhelm-Leen ER; Winkelmayer WC
Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
[TBL] [Abstract][Full Text] [Related]
13. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
[TBL] [Abstract][Full Text] [Related]
15. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis.
Macdougall IC; Matcham J; Gray SJ;
Nephrol Dial Transplant; 2003 Mar; 18(3):576-81. PubMed ID: 12584282
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
[TBL] [Abstract][Full Text] [Related]
17. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis.
Padhi D; Ni L; Cooke B; Marino R; Jang G
Clin Pharmacokinet; 2006; 45(5):503-10. PubMed ID: 16640455
[TBL] [Abstract][Full Text] [Related]
18. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease.
Hertel JE; Locay HR; Scarlata DS; Prathikanti R; Audhya PK
Mayo Clin Proc; 2006 Sep; 81(9):1188-94. PubMed ID: 16970215
[TBL] [Abstract][Full Text] [Related]
19. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
[TBL] [Abstract][Full Text] [Related]
20. Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.
Alsalimy N; Awaisu A
Int J Clin Pharm; 2014 Dec; 36(6):1115-25. PubMed ID: 25288147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]